Renata Evertz: THUNDER Study Sets a New Benchmark in Stroke Thrombectomy
Renata Evertz, Senior Director of Scientific Communications, Clinical Research Department at Penumbra, Inc., shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in the Journal of NeuroInterventional Surgery, adding:
“Proud to share that the primary results of the THUNDER study are now available online in Journal of NeuroInterventional Surgery.
This publication represents the first prospective, core lab adjudicated clinical evaluation of CAVT using the Thunderbolt System in patients with acute ischemic stroke due to emergent large vessel occlusion (ELVO).
A heartfelt thank you to our PIs, Dr. Fiorella and Dr. Donald Frei and to all of the investigators and study teams for their dedication and commitment to advancing stroke care.”
Title: Thunderbolt System for acute ischemic stroke secondary to large vessel occlusion: primary results of the THUNDER study
Authors: David Fiorella, Keith Woodward, Charles Matouk, Elad I. Levy, Ian Kaminsky, Kurt S. Reuland, Christopher Nickele, Giuseppe Ammirati, Robert M. Starke, William J. Ares, Michael Nahhas, Ashutosh Mahapatra, Ali Sultan-Qurraie, Bradley Bohnstedt, Alexandra R. Paul, Donald Frei.
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 3, 2026, 10:56Elias Othman: Can an Enzyme Involved in Cell Signaling Become a Target for Antithrombotic Drug Discovery?
-
Sep 3, 2026, 10:42Jared Griffard: Hemorrhagic Shock and Component Blood Transfusion
-
Sep 3, 2026, 10:31Alan Nurden: Comparing Antiplatelet and Antithrombin Therapies in Coronary Microcirculation
-
Sep 3, 2026, 08:53Jamie’s Journey Through a Decade with Immune Thrombocytopenia – ITP Support Association
-
Sep 3, 2026, 08:00Beth Meneley: When Transfusion Is Not an Option – HBOT for Exceptional Blood Loss Anemia
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease
-
Sep 3, 2026, 03:51Strengthening Bleeding Disorders Care in New Zealand – WFH